Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 22/11/2020
SIETES contiene 93161 citas

 
 
 1 a 20 de 441 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Pasternak B, Wintzell V, Melbye M, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Svanström H, Ueda P. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. BMJ 2020;369:29 de abril. [Ref.ID 103626]
2.Enlace a cita original Cita con resumen
Perkovic V, Jardine MJ, Neal BBompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, for the CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:13 de junio. [Ref.ID 103155]
4.Tiene citas relacionadas Cita con resumen
Odutayo A, Wong CX, Hsiao A, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ 2016;354:i4482. [Ref.ID 100671]
6. Cita con resumen
Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, Rosano GM, Davis BR, Ridao M, Zaragoza A, Montero-Corominas D, Tobías A, de la Fuente-Honrubia C, Tabarés-Seisdedos R, Hutton B. Cardiovascular and renal outcomes of renin–angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses. PLOS Medicine 2016:8 de marzo. [Ref.ID 100213]
7. Cita con resumen
Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol 2016:14 de abril. [Ref.ID 100161]
9.Tiene citas relacionadas Cita con resumen
Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME. Proton pump inhibitor use and risk of chronic kidney disease. JAMA Intern Med 2016;176:febrero. [Ref.ID 99957]
10.Tiene citas relacionadas Cita con resumen
Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, for the AMETHYST-DN Investigators. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 2015;314:151-61. [Ref.ID 99346]
11.Tiene citas relacionadas Cita con resumen
Winkelmayer WC. Treatment of hyperkalemia: from "hyper K" striketout to home run?. JAMA 2015;314:129-30. [Ref.ID 99345]
12.Tiene citas relacionadas
Greenland P, Lauer MS. Cholesterol lowering in 2015: still answering questions about how in whom. JAMA 2015;314:127-8. [Ref.ID 99344]
13. Cita con resumen
Hung SC , Chang YK, Liu JS, Kuo KL, Chen YH, Hsu CC, Tarng DC. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. The Lancet Diabetes Endocrinology 2015;3:605-14. [Ref.ID 99247]
14.Tiene citas relacionadas Cita con resumen
Shine B, McKnight RF, Leaver L, Geddes JR. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet 2015;386:461-8. [Ref.ID 99217]
15. Cita con resumen
Hung S-C, Chang Y-K, Liu J-S, Kuo KL, Chen YH, Hsu CC, Tarng DC. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. The Lancet Diabetes & Endocrinology 2015;3:605-14. [Ref.ID 99203]
16. Cita con resumen
Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, Wiebe N, Ruospo M, Wheller DC, Stripooli GFM. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 2015;385:2047-56. [Ref.ID 99157]
18. Cita con resumen
Anónimo. Sucroferric oxyhydroxide (Velphoro) for hyperphosphatemia. Drug Ther Bull 2014;56:76-7. [Ref.ID 98173]
19. Cita con resumen
Anónimo. FDA approves Jardiance to treat type 2 diabetes. U.S. Food and Drug Administration 2014:1 de agosto. [Ref.ID 97760]
20. Cita con resumen
Liu C-H, Huang C-F, Liu C-J, Dai C-Y, Liang C-C, Huang J-F, Hung P-H, Tsai H-B, Tsai M-K, Chen S-I, Lin J-W, Yang S-S, Su T-H, Yang H-C, Chen P-J, Chen D-S, Chuang W-L, Yu M-L, Kao J-H. Pegylated Interferon-a2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med 2013;159:729-38. [Ref.ID 96651]
Seleccionar todas
 
 1 a 20 de 441 siguiente >>